NewGene Looks to Shake up BRCA Market with Next-gen Sequencing-based Test

NewGene is initially targeting the UK market and patients with an increased hereditary risk for breast cancer for its pyrosequencing-based assay.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.